Inferra AI / Company / MCK
McKesson
MCK · Health Care
Last earnings Aug 5, 2026 · Next earnings Nov 4, 2026
Important announcements
Key results
Consolidated revenuequarter
$90.8 billion
Fourth Quarter Highlights Consolidated revenues of $90.8 billion increased 19%.
SEC original ↗McKesson — Earnings release (8-K exhibit)EX-99May 8, 2025
Consolidated revenuefull-year
$359.1 billion
Full Year Highlights Consolidated revenues of $359.1 billion increased 16%.
SEC original ↗McKesson — Earnings release (8-K exhibit)EX-99May 8, 2025
Free cash flowfull-year
$5.2 billion
Cash flow from operations of $6.1 billion and Free Cash Flow of $5.2 billion.
SEC original ↗McKesson — Earnings release (8-K exhibit)EX-99May 8, 2025
Revenuefull-year
19%
McKesson delivered strong fourth quarter performance reporting revenue growth of 19% and Adjusted Earnings per Diluted Share growth of 64%.
SEC original ↗McKesson — Earnings release (8-K exhibit)EX-99May 8, 2025
Capexquarter
$859 million
During the fiscal year, McKesson generated cash from operations of $6.1 billion, and invested $859 million in capital expenditures, resulting in Free Cash Flow of $5.2 billion.
SEC original ↗McKesson — Earnings release (8-K exhibit)EX-99May 8, 2025
Free cash flowquarter
$5.2 billion
During the fiscal year, McKesson generated cash from operations of $6.1 billion, and invested $859 million in capital expenditures, resulting in Free Cash Flow of $5.2 billion.
SEC original ↗McKesson — Earnings release (8-K exhibit)EX-99May 8, 2025
Revenuequarter
$83.2 billion
Pharmaceutical Segment Fourth Quarter Revenues were $83.2 billion, an increase of 21%, driven by increased prescription volumes from retail national customers and growth in the distribution of specialty products, including higher volumes in oncology.
SEC original ↗McKesson — Earnings release (8-K exhibit)EX-99May 8, 2025
Full Year Revenues were $327.7 billion, an increase of 18%, driven by increased prescription volumes from retail national customers and growth in the distribution of specialty products, including higher volumes in oncology.
SEC original ↗McKesson — Earnings release (8-K exhibit)EX-99May 8, 2025
Prescription Technology Solutions Segment Fourth Quarter Revenues were $1.3 billion, an increase of 13%, driven by increased prescription volumes in the third-party logistics and technology services businesses.
SEC original ↗McKesson — Earnings release (8-K exhibit)EX-99May 8, 2025
AI analysis
Q1 2025 · reported May 8, 2025
Based on: Earnings release + parent 8-K + 10-Q — transcript not held
The quarter in charts
Headline figures
| Metric | Q1 2025 | Prior qtr | Year ago |
|---|---|---|---|
| Consolidated revenue | $90.8 billion | — | — |
| Capex | $859 million | — | — |
| Free cash flow | $5.2 billion | — | — |
| Revenue | $83.2 billion | — | — |
Guidance · company-stated
Direction: raised
No guidance located in the held release
“1 McKESSON REPORTS FISCAL 2027 FIRST QUARTER RESULTS AND RAISES FULL YEAR ADJUSTED EPS GUIDANCE IRVING, Texas, August 5, 2026 - McKesson Corporation (NYSE MCK) today announced results for the first quarter ended June 30, 2026.”
Cash flow & capex
Capital allocation
For the full year, McKesson returned $3.5 billion of cash to shareholders, which included $3.1 billion of common stock repurchases and $345 million of dividend payments.
Event summary
Earnings per diluted share of $10.01 increased $3.99
Based on: Earnings release + parent 8-K + 10-Q — transcript not held
Guidance & outlook
No guidance located in the held release
Capital allocation
For the full year, McKesson returned $3.5 billion of cash to shareholders, which included $3.1 billion of common stock repurchases and $345 million of dividend payments.
SEC original ↗McKesson — Earnings release (8-K exhibit)EX-99May 8, 2025
During the fiscal year, McKesson generated cash from operations of $6.1 billion, and invested $859 million in capital expenditures, resulting in Free Cash Flow of $5.2 billion.
SEC original ↗McKesson — Earnings release (8-K exhibit)EX-99May 8, 2025
While not all-inclusive, other adjustments may include other asset impairments gains or losses from debt extinguishment and other similar substantive and or infrequent items as deemed appropriate.
SEC original ↗McKesson — Earnings release (8-K exhibit)EX-99May 8, 2025
We believe free cash flow is important to management and useful to investors as a supplemental measure as it indicates the cash flow available for working capital needs, re-investment opportunities, strategic acquisitions, share repurchases, dividend payments, or other strategic uses of cash.
SEC original ↗McKesson — Earnings release (8-K exhibit)EX-99May 8, 2025
The payment made upon closing was from cash on hand and the net proceeds from the May 30, 2025 public debt offering.
SEC original ↗McKesson — 10-Q Quarterly report10-QAug 5, 2026
Refer to Financial Note 8, Debt and Financing Activities, for additional information on the public debt offering.
SEC original ↗McKesson — 10-Q Quarterly report10-QAug 5, 2026
Strategy & priorities
This marks another year of strong financial results, above our long-term targets, underpinned by operational execution against our strategic priorities, and disciplined and focused capital deployment, said Brian Tyler, chief executive officer.
SEC original ↗McKesson — Earnings release (8-K exhibit)EX-99May 8, 2025
The strength of our core pharmaceutical distribution business, expansion of our Oncology platform, and continued growth of our differentiated biopharma solutions businesses led to strong results.
SEC original ↗McKesson — Earnings release (8-K exhibit)EX-99May 8, 2025
As we look ahead to fiscal 2026, we are well positioned to build on our operating momentum, accelerate growth through our strategic priorities, and target investments to accelerate growth and modernize the portfolio.
SEC original ↗McKesson — Earnings release (8-K exhibit)EX-99May 8, 2025
1 See below under Fiscal 2026 Outlook for full explanation Strategic Portfolio Update for the Medical-Surgical Solutions Segment Today McKesson is announcing its intention to separate its Medical-Surgical Solutions segment into an independent company ( NewCo ).
SEC original ↗McKesson — Earnings release (8-K exhibit)EX-99May 8, 2025
Disciplined portfolio management is a hallmark of our enterprise strategy.
SEC original ↗McKesson — Earnings release (8-K exhibit)EX-99May 8, 2025
Risks & headwinds
In the past year, McKesson's biopharma services platform helped patients save more than $10 billion on brand and specialty medications, helped to prevent 12 million prescriptions from being abandoned due to affordability challenges, and helped patients access their medicine more than 100 million times.
SEC original ↗McKesson — Earnings release (8-K exhibit)EX-99May 8, 2025
McKesson cannot reasonably forecast LIFO inventory-related adjustments, certain litigation loss and gain contingencies, restructuring, impairment and related charges, and other adjustments, which are difficult to predict and estimate.
SEC original ↗McKesson — Earnings release (8-K exhibit)EX-99May 8, 2025
Any discussion of our intent to separate our Medical-Surgical Solutions segment into an independent company, other anticipated or completed transactions, including the anticipated closings thereof,or synergies expected therefrom, litigation outcomes, financial outlook, guidance, trends, strategy, plans, assumptions, expectations, commitments, and intentions may also include forward-looking statements.
SEC original ↗McKesson — Earnings release (8-K exhibit)EX-99May 8, 2025
Forward-looking statements involve risks and uncertainties that could cause actual results to differ materially from those projected, anticipated, or implied.
SEC original ↗McKesson — Earnings release (8-K exhibit)EX-99May 8, 2025
Although it is not possible to predict or identify all such risks and uncertainties, we encourage investors to read the risk factors described in our publicly available filings with the Securities and Exchange Commission and news releases.
SEC original ↗McKesson — Earnings release (8-K exhibit)EX-99May 8, 2025
(4) Claims and litigation charges, net for the year ended March 31, 2025 includes pre-tax charges of $114 million ($86 million after-tax) related to our estimated liability for opioid-related claims of a nationwide group of certain third-party payors.
SEC original ↗McKesson — Earnings release (8-K exhibit)EX-99May 8, 2025
Earnings deck slides
0 decks with slide viewMcKesson — Presentation / slide deck (8-K exhibit) — Slide view unavailable — this deck was filed as a web document, whose text has no page boundaries.
Competitors
Competitors & peers
Same GICS sector — classification peers, not declared competitors
Filings
67 documents- Q3 2026
- 8-KMCK
Oct 6, 2026
- Q2 2026
- 8-KMCK
Aug 28, 2026
- 10-QMCK
Aug 5, 2026
- 8-KMCK
Aug 5, 2026
- 8-KMCK
Jul 24, 2026
- 8-KMCK
Jul 1, 2026
- Q1 2026
- 8-KMCK
Jun 12, 2026
- 10-KMCK
May 8, 2026
- 8-KMCK
May 7, 2026
- 8-KMCK
Apr 28, 2026
- 8-KMCK
Apr 6, 2026
- Q4 2025
- 8-KMCK
Mar 6, 2026
- EX-99MCK
Mar 6, 2026
- 8-KMCK
Mar 5, 2026
- EX-99MCK
Mar 5, 2026
- 10-QMCK
Feb 4, 2026
- 8-KMCK
Feb 4, 2026
- Q3 2025
- 10-QMCK
Nov 6, 2025
- 8-KMCK
Nov 5, 2025
- Q2 2025
- 8-KMCK
Sep 23, 2025
- EX-99MCK
Sep 23, 2025
- 8-KMCK
Sep 18, 2025
- 10-QMCK
Aug 6, 2025
- 8-KMCK
Aug 6, 2025
- 8-KMCK
Aug 1, 2025
- Q1 2025
- 8-KMCK
Jun 9, 2025
- 8-KMCK
May 30, 2025
- EX-99MCK
May 30, 2025
- 10-KMCK
May 9, 2025
- 8-KMCK
May 8, 2025
- Q4 2024
- 10-QMCK
Feb 6, 2025
- 8-K/AMCK
Feb 5, 2025
- 8-KMCK
Feb 5, 2025
- Q3 2024
- 10-QMCK
Nov 7, 2024
- 8-KMCK
Nov 6, 2024
- Q2 2024
- 8-KMCK
Sep 10, 2024
- 8-KMCK
Sep 5, 2024
- 8-KMCK
Aug 26, 2024
- EX-99MCK
Aug 26, 2024
- 8-KMCK
Aug 7, 2024
- 10-QMCK
Aug 7, 2024
- 8-KMCK
Aug 2, 2024
- Q1 2024
- 8-KMCK
Jun 3, 2024
- EX-99MCK
Jun 3, 2024
- 10-KMCK
May 8, 2024
- 8-KMCK
May 7, 2024
- Q4 2023
- 10-QMCK
Feb 8, 2024
- 8-KMCK
Feb 7, 2024
- 8-KMCK
Jan 9, 2024
- EX-99MCK
Jan 9, 2024
- Q3 2023
- 8-KMCK
Nov 7, 2023
- 10-QMCK
Nov 2, 2023
- 8-KMCK
Nov 1, 2023
- 8-KMCK
Oct 16, 2023
- 8-KMCK
Oct 3, 2023
- Q2 2023
- 8-KMCK
Aug 2, 2023
- 10-QMCK
Aug 2, 2023
- 8-KMCK
Jul 25, 2023
- Q1 2023
- 8-KMCK
Jun 16, 2023
- 8-KMCK
Jun 7, 2023
- 10-KMCK
May 9, 2023
- 8-KMCK
May 8, 2023
- 8-KMCK
Apr 28, 2023
- Q4 2022
- 8-KMCK
Feb 15, 2023
- 10-QMCK
Feb 2, 2023
- 8-KMCK
Feb 1, 2023
- Q3 2022
- 8-KMCK
Nov 7, 2022
Earnings releases
18 documents- Q3 2026
- EX-99MCK
Oct 6, 2026
- Q2 2026
- EX-99MCK
Aug 5, 2026
- Q1 2026
- EX-99MCK
May 7, 2026
- Q4 2025
- EX-99MCK
Feb 4, 2026
- Q3 2025
- EX-99MCK
Nov 5, 2025
- Q2 2025
- EX-99MCK
Aug 6, 2025
- Q1 2025
- EX-99MCK
May 8, 2025
- Q4 2024
- EX-99MCK
Feb 5, 2025
- EX-99MCK
Feb 5, 2025
- Q3 2024
- EX-99MCK
Nov 6, 2024
- Q2 2024
- EX-99MCK
Sep 10, 2024
- EX-99MCK
Aug 7, 2024
- Q1 2024
- EX-99MCK
May 7, 2024
- Q4 2023
- EX-99MCK
Feb 7, 2024
- Q3 2023
- EX-99MCK
Nov 1, 2023
- Q2 2023
- EX-99MCK
Aug 2, 2023
- Q1 2023
- EX-99MCK
May 8, 2023
- Q4 2022
- EX-99MCK
Feb 1, 2023
Presentations
1 document- Q2 2025
- MCKDeck
Transcripts
0 documentsNo transcripts for McKesson are held in this edition of the library.
Mentioned by
7 companiesOther tracked companies whose held documents mention McKesson by name or ticker. A mention is counted once per document, from the document text the library holds.
“…minority interest of approximately 49%. The transaction also establishes a framework for McKesson’s future acquisition of CD&R’s interest in Option Care Health, subject to specified conditions and regulatory approvals.… …will become a privately held”
“and uncertainties; we may be unsuccessful in achieving… …per common share attributable to McKesson Corporation (a) Diluted $ 5.15 $ 6.25 (18) % Basic $ 5.17 $ 6.28 (18) % Dividends declared per common share $ 0.82 $ 0.71 15 % ”
“…their medicine more than 100 million times. • On April 2, 2025, McKesson announced completion of the acquisition of an 80% controlling interest of PRISM Vision Holdings, LLC, a leading provider of general ophthalmology… …att”
“ansactions described in this press release; we from time to time record… …attributable to McKesson Corporation (a) Diluted $ 6.95 $ 4.42 57 % $ 15.80 $ 16.39 (4) % Basic $ 6.98 $ 4.45 57 % $ 15.88 $ 16.49 (4) % Dividends declare”
“eal estate, investor relations, internal audit, merger & acquisition and tax functions at McKesson. In addition to leading McKesson’s Enterprise Finance organization, he… …accounting, financial planning and analysis, treasury, real estate, investor r”
“ansactions described in this press release; we from time to time record… …attributable to McKesson Corporation (a) Diluted $ 6.95 $ 4.42 57 % $ 15.80 $ 16.39 (4) % Basic $ 6.98 $ 4.45 57 % $ 15.88 $ 16.49 (4) % Dividends declare”
Option Care Health, Inc. (OPCH)
“…minority interest of approximately 49%. The transaction also establishes a framework for McKesson’s future acquisition of CD&R’s interest in Option Care Health, subject to specified conditions and regulatory approvals.… …become a privately held comp”
See also the earnings calendar for every tracked company’s next earnings date.